Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

SARA SHELBY FRIEDMAN

Allopathic & Osteopathic Physicians Obstetrics & Gynecology

NPI
1649318569
CMS profile
979795
Location
ALBUQUERQUE, NM

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$1,724.29

6 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

Nature of paymentAmountRecords
Travel and Lodging $1,129.38 3
Food and Beverage $594.91 3

By paying entity

PY2023 · entire year · sorted by reported total

Paying entityAmountRecords
ModernaTX, Inc. $1,663.92 4
Merck Sharp & Dohme LLC $60.37 2

Page 1 of 1; records 1–6 of 6 matching records. This page contains 6 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

SARA SHELBY FRIEDMAN

NPI 1649318569 · CMS profile ID 979795

Allopathic & Osteopathic Physicians / Obstetrics & Gynecology

ALBUQUERQUE, NM

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–6 of 6 matching records. This page contains 6 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1649318569?year=2023&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
SARA SHELBY FRIEDMAN, NPI 1649318569, CMS profile ID 979795. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–6 of 6 matching records. This page contains 6 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1649318569?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). SARA SHELBY FRIEDMAN, NPI 1649318569, CMS profile ID 979795. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–6 of 6 matching records. This page contains 6 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1649318569?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
SARA SHELBY FRIEDMAN, NPI 1649318569, CMS profile ID 979795, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–6 of 6 matching records. This page contains 6 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1649318569?year=2023&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

6 matching records · $1,724.29 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 6 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–6 of 6.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Merck Sharp & Dohme LLC $25.3712/07/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1048269819 CMS
Merck Sharp & Dohme LLC $35.0012/06/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1048269817 CMS
ModernaTX, Inc. $534.5408/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1056980807 CMS
ModernaTX, Inc. $572.8008/17/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1056980843 CMS
ModernaTX, Inc. $206.7208/17/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1056980859 CMS
ModernaTX, Inc. $349.8608/17/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1056980863 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $169.09 11
PY2023 $1,724.29 6
PY2024 $3,024.97 16

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2023, 2024
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2023 , PY2024
Generated from
OP_DTL_GNRL_PGYR2024_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $1,296,266.41 159
PY2024 Principal investigator $1,078,411.75 127
PY2023 Principal investigator $776,040.20 596
PY2022 Principal investigator $318,257.95 46

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

127 records in PY2024

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Merck Sharp & Dohme LLC $53,798.18 12/31/2024 Non-covered Recipient Entity
Velocity Clinical Research, Albuquerque
A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Children and Adolescents With Increased Risk of Pneumococcal Disease No dispute reported 06/30/2026 1136434467
Principal investigator 1 ModernaTX, Inc. $19,181.45 12/23/2024 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A PHASE 3, RANDOMIZED, OBSERVER-BLINDED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF MRNA-1403, A MULTIVALENT CANDIDATE VACCINE TO PREVENT NOROVIRUS ACUTE GASTROENTERITIS IN ADULTS 18 YEARS OF AGE No dispute reported 06/30/2026 1147142962
Principal investigator 1 ModernaTX, Inc. $31,541.90 12/20/2024 Non-covered Recipient Entity
Velocity Clinical Research - Albuquerque - PPDS
A Phase 4, Randomized, Observer-blind, Placebo-controlled, Crossover Study to Assess Cardiac Troponin Levels after mRNA-1273.712 Vaccine in Participants 12 through 30 years of Age No dispute reported 06/30/2026 1147177406
Principal investigator 1 Currax Pharmaceuticals LLC $1,100.00 12/19/2024 Non-covered Recipient Entity
Velocity Clinical Research Inc
NB (Contrave) Cardiovascular Outcomes Trial No dispute reported 06/30/2026 1089521437
Principal investigator 1 ModernaTX, Inc. $877.50 12/18/2024 Non-covered Recipient Entity
Velocity Clinical Research - Albuquerque - PPDS
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1147177396
Principal investigator 1 Vertex Pharmaceuticals Incorporated $2,600.00 12/18/2024 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH ALBUQUERQUE
A Phase 3, Open-label Study Evaluating the Long-term Safety and Effectiveness of Suzetrigine in Subjects With Pain Associated With Diabetic Peripheral Neuropathy No dispute reported 06/30/2026 1155491075
Principal investigator 1 ModernaTX, Inc. $1,247.50 12/13/2024 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1147142834
Principal investigator 1 ModernaTX, Inc. $790.40 12/13/2024 Non-covered Recipient Entity
Velocity Clinical Research - Albuquerque - PPDS
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1147177394
Principal investigator 1 ModernaTX, Inc. $249.45 12/13/2024 Non-covered Recipient Entity
Velocity Clinical Research - Albuquerque - PPDS
A PHASE 3, RANDOMIZED, OBSERVER-BLINDED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF MRNA-1403, A MULTIVALENT CANDIDATE VACCINE TO PREVENT NOROVIRUS ACUTE GASTROENTERITIS IN ADULTS 18 YEARS OF AGE No dispute reported 06/30/2026 1147177408
Principal investigator 1 ModernaTX, Inc. $300.00 12/06/2024 Non-covered Recipient Entity
Velocity Clinical Research - Albuquerque - PPDS
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1147177398
Principal investigator 1 ModernaTX, Inc. $2,176.07 12/04/2024 Non-covered Recipient Entity
Velocity Clinical Research - Albuquerque - PPDS
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1147177392
Principal investigator 1 ModernaTX, Inc. $12,940.38 11/28/2024 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1147142598
Principal investigator 1 ModernaTX, Inc. $19,398.05 11/27/2024 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A PHASE 3, RANDOMIZED, OBSERVER-BLINDED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF MRNA-1403, A MULTIVALENT CANDIDATE VACCINE TO PREVENT NOROVIRUS ACUTE GASTROENTERITIS IN ADULTS 18 YEARS OF AGE No dispute reported 06/30/2026 1147142672
Principal investigator 1 ModernaTX, Inc. $307.45 11/22/2024 Non-covered Recipient Entity
Velocity Clinical Research - Albuquerque - PPDS
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1147177362
Principal investigator 1 ModernaTX, Inc. $500.00 11/22/2024 Non-covered Recipient Entity
Velocity Clinical Research - Albuquerque - PPDS
A Phase 3, randomized, observerblind, activecontrol study to evaluate the safety, reactogenicity, and immunogenicity of mRNA1083 (SARSCoV2 and influenza) vaccine in healthy adult participants, 50 years of age. No dispute reported 06/30/2026 1147177366
Principal investigator 1 ModernaTX, Inc. $325.00 11/22/2024 Non-covered Recipient Entity
Velocity Clinical Research - Albuquerque - PPDS
A Phase 3, randomized, observerblind, activecontrol study to evaluate the safety, reactogenicity, and immunogenicity of mRNA1083 (SARSCoV2 and influenza) vaccine in healthy adult participants, 50 years of age. No dispute reported 06/30/2026 1147177368
Principal investigator 1 ModernaTX, Inc. $2,000.00 11/22/2024 Non-covered Recipient Entity
Velocity Clinical Research - Albuquerque - PPDS
A Phase 3, randomized, observerblind, activecontrol study to evaluate the safety, reactogenicity, and immunogenicity of mRNA1083 (SARSCoV2 and influenza) vaccine in healthy adult participants, 50 years of age. No dispute reported 06/30/2026 1147177370
Principal investigator 1 ModernaTX, Inc. $3,300.00 11/22/2024 Non-covered Recipient Entity
Velocity Clinical Research - Albuquerque - PPDS
A Phase 3, randomized, observerblind, activecontrol study to evaluate the safety, reactogenicity, and immunogenicity of mRNA1083 (SARSCoV2 and influenza) vaccine in healthy adult participants, 50 years of age. No dispute reported 06/30/2026 1147177372
Principal investigator 1 ModernaTX, Inc. $597.25 11/22/2024 Non-covered Recipient Entity
Velocity Clinical Research - Albuquerque - PPDS
A Phase 3, randomized, observerblind, activecontrol study to evaluate the safety, reactogenicity, and immunogenicity of mRNA1083 (SARSCoV2 and influenza) vaccine in healthy adult participants, 50 years of age. No dispute reported 06/30/2026 1147177374
Principal investigator 1 ModernaTX, Inc. $14,262.80 11/21/2024 Non-covered Recipient Entity
Velocity Clinical Research - Albuquerque - PPDS
A Phase 4, Randomized, Observer-blind, Placebo-controlled, Crossover Study to Assess Cardiac Troponin Levels after mRNA-1273.712 Vaccine in Participants 12 through 30 years of Age No dispute reported 06/30/2026 1147177376
Principal investigator 1 Novo Nordisk AS $4.50 11/20/2024 Non-covered Recipient Entity
VELOCITY CLIN RES ALBUQUERQUE
NN9388-7741 No dispute reported 06/30/2026 1097205921
Principal investigator 1 ModernaTX, Inc. $68.30 11/19/2024 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH- NEW MEXICO
A PHASE 3, RANDOMIZED, OBSERVER-BLINDED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF MRNA-1403, A MULTIVALENT CANDIDATE VACCINE TO PREVENT NOROVIRUS ACUTE GASTROENTERITIS IN ADULTS 18 YEARS OF AGE No dispute reported 06/30/2026 1147152487
Principal investigator 1 Currax Pharmaceuticals LLC $2,728.41 11/14/2024 Non-covered Recipient Entity
Velocity Clinical Research Inc
NB (Contrave) Cardiovascular Outcomes Trial No dispute reported 06/30/2026 1089521042
Principal investigator 1 ModernaTX, Inc. $3,753.10 11/13/2024 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1147142554
Principal investigator 1 VERTEX PHARMACEUTICALS INCORPORATED $4,639.59 11/13/2024 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH ALBUQUERQUE
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-design Study of the Efficacy and Safety of Suzetrigine in Subjects With Painful Diabetic Peripheral Neuropathy No dispute reported 06/30/2026 1095480810
Principal investigator 1 ModernaTX, Inc. $7,000.00 11/08/2024 Non-covered Recipient Entity
Velocity Clinical Research - Albuquerque - PPDS
A Phase 4, Randomized, Observer-blind, Placebo-controlled, Crossover Study to Assess Cardiac Troponin Levels after mRNA-1273.712 Vaccine in Participants 12 through 30 years of Age No dispute reported 06/30/2026 1147177378
Principal investigator 1 Currax Pharmaceuticals LLC $247.00 11/07/2024 Non-covered Recipient Entity
Velocity Clinical Research Inc
NB (Contrave) Cardiovascular Outcomes Trial No dispute reported 06/30/2026 1089519809
Principal investigator 1 ModernaTX, Inc. $3,470.00 11/04/2024 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 2, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial Virus Disease No dispute reported 06/30/2026 1147142606
Principal investigator 1 ModernaTX, Inc. $102.45 10/31/2024 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH- NEW MEXICO
A PHASE 3, RANDOMIZED, OBSERVER-BLINDED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF MRNA-1403, A MULTIVALENT CANDIDATE VACCINE TO PREVENT NOROVIRUS ACUTE GASTROENTERITIS IN ADULTS 18 YEARS OF AGE No dispute reported 06/30/2026 1147152485
Principal investigator 1 Novo Nordisk AS $53.70 10/31/2024 Non-covered Recipient Entity
VELOCITY CLIN RES ALBUQUERQUE
NN9388-7741 No dispute reported 06/30/2026 1097205369
Principal investigator 1 ModernaTX, Inc. $3,698.24 10/25/2024 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1147135395
Principal investigator 1 Currax Pharmaceuticals LLC $5,400.00 10/24/2024 Non-covered Recipient Entity
Velocity Clinical Research Inc
NB (Contrave) Cardiovascular Outcomes Trial No dispute reported 06/30/2026 1089519652
Principal investigator 1 Currax Pharmaceuticals LLC $3,300.00 10/24/2024 Non-covered Recipient Entity
Velocity Clinical Research Inc
NB (Contrave) Cardiovascular Outcomes Trial No dispute reported 06/30/2026 1089520810
Principal investigator 1 SANOFI PASTEUR INC. $1,536.97 10/23/2024 Non-covered Recipient Entity
Velocity Clinical Research,inc
A Phase I/II, Randomized, Descriptive, Safety and Immunogenicity Study to Assess Pentavalent Meningococcal ABCYW Vaccine Formulations in Adults (18 to 25 Years of Age) and Adolescents (10 to 17 Years of Age). No dispute reported 06/30/2026 1128703446
Principal investigator 1 ModernaTX, Inc. $9,932.86 10/18/2024 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
An Open-Label, Phase 3 Study to Evaluate the Safety and Immunogenicity of the mRNA1273.214 Vaccine for SARS-CoV-2 Variants of Concern in Participants Aged 6 Months to < 6 Years No dispute reported 06/30/2026 1147135435
Principal investigator 1 ModernaTX, Inc. $2,976.35 10/18/2024 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
An Open-Label, Phase 3 Study to Evaluate the Safety and Immunogenicity of the mRNA1273.214 Vaccine for SARS-CoV-2 Variants of Concern in Participants Aged 6 Months to < 6 Years No dispute reported 06/30/2026 1147135437
Principal investigator 1 Vertex Pharmaceuticals Incorporated $18,256.05 10/18/2024 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH ALBUQUERQUE
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-design Study of the Efficacy and Safety of Suzetrigine in Subjects With Painful Diabetic Peripheral Neuropathy No dispute reported 06/30/2026 1155491076
Principal investigator 1 ModernaTX, Inc. $6,800.00 10/14/2024 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A PHASE 3, RANDOMIZED, OBSERVER-BLINDED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF MRNA-1403, A MULTIVALENT CANDIDATE VACCINE TO PREVENT NOROVIRUS ACUTE GASTROENTERITIS IN ADULTS 18 YEARS OF AGE No dispute reported 06/30/2026 1147142340
Principal investigator 1 ModernaTX, Inc. $5,550.00 10/11/2024 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
Phase 1/2a randomized, observer-blind, placebo-controlled, dose-ranging study of safety and immunogenicity of mRNA-1647 cytomegalovirus (CMV) vaccine in participants 9 to 15 years of age and open-label study of safety and immunogenicity of mRNA-1647 CMV vaccine in participants 9 to 25 years of age No dispute reported 06/30/2026 1147135345
Principal investigator 1 ModernaTX, Inc. $2,000.00 10/11/2024 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
Phase 1/2a randomized, observer-blind, placebo-controlled, dose-ranging study of safety and immunogenicity of mRNA-1647 cytomegalovirus (CMV) vaccine in participants 9 to 15 years of age and open-label study of safety and immunogenicity of mRNA-1647 CMV vaccine in participants 9 to 25 years of age No dispute reported 06/30/2026 1147135347
Principal investigator 1 ModernaTX, Inc. $850.00 10/11/2024 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
Phase 1/2a randomized, observer-blind, placebo-controlled, dose-ranging study of safety and immunogenicity of mRNA-1647 cytomegalovirus (CMV) vaccine in participants 9 to 15 years of age and open-label study of safety and immunogenicity of mRNA-1647 CMV vaccine in participants 9 to 25 years of age No dispute reported 06/30/2026 1147135349
Principal investigator 1 ModernaTX, Inc. $10,171.45 10/02/2024 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
Phase 1/2a randomized, observer-blind, placebo-controlled, dose-ranging study of safety and immunogenicity of mRNA-1647 cytomegalovirus (CMV) vaccine in participants 9 to 15 years of age and open-label study of safety and immunogenicity of mRNA-1647 CMV vaccine in participants 9 to 25 years of age No dispute reported 06/30/2026 1147135341
Principal investigator 1 ModernaTX, Inc. $8,260.00 10/02/2024 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
Phase 1/2a randomized, observer-blind, placebo-controlled, dose-ranging study of safety and immunogenicity of mRNA-1647 cytomegalovirus (CMV) vaccine in participants 9 to 15 years of age and open-label study of safety and immunogenicity of mRNA-1647 CMV vaccine in participants 9 to 25 years of age No dispute reported 06/30/2026 1147135343
Principal investigator 1 ModernaTX, Inc. $7,526.00 10/02/2024 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
Phase 1/2a randomized, observer-blind, placebo-controlled, dose-ranging study of safety and immunogenicity of mRNA-1647 cytomegalovirus (CMV) vaccine in participants 9 to 15 years of age and open-label study of safety and immunogenicity of mRNA-1647 CMV vaccine in participants 9 to 25 years of age No dispute reported 06/30/2026 1147135351
Principal investigator 1 Merck Sharp & Dohme LLC $296.94 09/30/2024 Non-covered Recipient Entity
Velocity Clinical Research, Albuquerque
A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Children and Adolescents With Increased Risk of Pneumococcal Disease No dispute reported 06/30/2026 1136436578
Principal investigator 1 ModernaTX, Inc. $5,000.00 09/27/2024 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A PHASE 3, RANDOMIZED, OBSERVER-BLINDED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF MRNA-1403, A MULTIVALENT CANDIDATE VACCINE TO PREVENT NOROVIRUS ACUTE GASTROENTERITIS IN ADULTS 18 YEARS OF AGE No dispute reported 06/30/2026 1147142092
Principal investigator 1 Currax Pharmaceuticals LLC $1,100.00 09/26/2024 Non-covered Recipient Entity
Velocity Clinical Research Inc
NB (Contrave) Cardiovascular Outcomes Trial No dispute reported 06/30/2026 1089520559
Principal investigator 1 Currax Pharmaceuticals LLC $653.26 09/26/2024 Non-covered Recipient Entity
Velocity Clinical Research Inc
NB (Contrave) Cardiovascular Outcomes Trial No dispute reported 06/30/2026 1089520650
Principal investigator 1 AstraZeneca Pharmaceuticals LP $17,450.00 09/25/2024 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH
A Phase IIb Randomized Double blind Placebo controlled and Open label Active Comparator Study to Evaluate the Efficacy Safety and Tolerability of AZD5004 in Adults with Type 2 Diabetes Mellitus No dispute reported 06/30/2026 1110840076
Principal investigator 1 ModernaTX, Inc. $890.00 09/25/2024 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1147135091
Principal investigator 1 ModernaTX, Inc. $1,000.00 09/25/2024 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1147135093
Principal investigator 1 ModernaTX, Inc. $500.00 09/25/2024 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1147135095
Principal investigator 1 ModernaTX, Inc. $44,935.03 09/25/2024 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1147142008
Principal investigator 1 ModernaTX, Inc. $2,900.00 09/23/2024 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1147141958
Principal investigator 1 Novo Nordisk AS $3.00 09/19/2024 Non-covered Recipient Entity
VELOCITY CLIN RES ALBUQUERQUE
NN9388-7741 No dispute reported 06/30/2026 1097184710
Principal investigator 1 Novo Nordisk AS $17.90 09/19/2024 Non-covered Recipient Entity
VELOCITY CLIN RES ALBUQUERQUE
NN9388-7741 No dispute reported 06/30/2026 1097191777
Principal investigator 1 ModernaTX, Inc. $2,781.22 09/18/2024 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1147135089
Principal investigator 1 ModernaTX, Inc. $9,152.60 09/18/2024 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 2, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial Virus Disease No dispute reported 06/30/2026 1147142032
Principal investigator 1 ModernaTX, Inc. $399.12 09/13/2024 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH- NEW MEXICO
A PHASE 3, RANDOMIZED, OBSERVER-BLINDED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF MRNA-1403, A MULTIVALENT CANDIDATE VACCINE TO PREVENT NOROVIRUS ACUTE GASTROENTERITIS IN ADULTS 18 YEARS OF AGE No dispute reported 06/30/2026 1147152483
Principal investigator 1 Currax Pharmaceuticals LLC $325.00 09/05/2024 Non-covered Recipient Entity
Velocity Clinical Research Inc
NB (Contrave) Cardiovascular Outcomes Trial No dispute reported 06/30/2026 1089519565
Principal investigator 1 ModernaTX, Inc. $2,927.60 09/03/2024 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1147135087
Principal investigator 1 ModernaTX, Inc. $157,464.77 09/02/2024 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1147141892
Principal investigator 1 AstraZeneca Pharmaceuticals LP $17,234.00 08/23/2024 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH
a phase 3,global,randomized,modified double blind,placebo controlled,study to evaluate the efficacy,immunogenicity,and safety of IVX A12,a respiratory syncytial virus RSV and human metapneumovirus hMPV virus like particle VLP vaccine in adults 60 years of age and older No dispute reported 06/30/2026 1110840244
Principal investigator 1 ModernaTX, Inc. $2,687.36 08/21/2024 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1147134769
Principal investigator 1 ModernaTX, Inc. $21,563.84 08/21/2024 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
An Open-Label, Phase 3 Study to Evaluate the Safety and Immunogenicity of the mRNA1273.214 Vaccine for SARS-CoV-2 Variants of Concern in Participants Aged 6 Months to < 6 Years No dispute reported 06/30/2026 1147134819
Principal investigator 1 ModernaTX, Inc. $2,000.00 08/01/2024 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, randomized, observerblind, activecontrol study to evaluate the safety, reactogenicity, and immunogenicity of mRNA1083 (SARSCoV2 and influenza) vaccine in healthy adult participants, 50 years of age. No dispute reported 06/30/2026 1147134457
Principal investigator 1 ModernaTX, Inc. $11,347.65 08/01/2024 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, randomized, observerblind, activecontrol study to evaluate the safety, reactogenicity, and immunogenicity of mRNA1083 (SARSCoV2 and influenza) vaccine in healthy adult participants, 50 years of age. No dispute reported 06/30/2026 1147134459
Principal investigator 1 ModernaTX, Inc. $32,172.96 08/01/2024 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1147141680
Principal investigator 1 ModernaTX, Inc. $22.70 07/30/2024 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH- NEW MEXICO
A Phase 2, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial Virus Disease No dispute reported 06/30/2026 1147152469
Principal investigator 1 ModernaTX, Inc. $2,076.30 07/29/2024 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 2, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial Virus Disease No dispute reported 06/30/2026 1147140638
Principal investigator 1 Currax Pharmaceuticals LLC $7,700.00 07/18/2024 Non-covered Recipient Entity
Velocity Clinical Research Inc
NB (Contrave) Cardiovascular Outcomes Trial No dispute reported 06/30/2026 1089520284
Principal investigator 1 ModernaTX, Inc. $1,223.88 07/17/2024 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1147134293
Principal investigator 1 ModernaTX, Inc. $14,892.86 07/03/2024 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
Phase 1/2a randomized, observer-blind, placebo-controlled, dose-ranging study of safety and immunogenicity of mRNA-1647 cytomegalovirus (CMV) vaccine in participants 9 to 15 years of age and open-label study of safety and immunogenicity of mRNA-1647 CMV vaccine in participants 9 to 25 years of age No dispute reported 06/30/2026 1147134229
Principal investigator 1 SANOFI PASTEUR INC. $3,073.94 06/28/2024 Non-covered Recipient Entity
Velocity Clinical Research,inc
A Phase I/II, Randomized, Descriptive, Safety and Immunogenicity Study to Assess Pentavalent Meningococcal ABCYW Vaccine Formulations in Adults (18 to 25 Years of Age) and Adolescents (10 to 17 Years of Age). No dispute reported 06/30/2026 1128703248
Principal investigator 1 ModernaTX, Inc. $3,437.10 06/27/2024 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 2, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial Virus Disease No dispute reported 06/30/2026 1147141584
Principal investigator 1 ModernaTX, Inc. $6,452.88 06/26/2024 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1147133957
Principal investigator 1 Currax Pharmaceuticals LLC $13,500.00 06/13/2024 Non-covered Recipient Entity
Velocity Clinical Research Inc
NB (Contrave) Cardiovascular Outcomes Trial No dispute reported 06/30/2026 1089519079
Principal investigator 1 Currax Pharmaceuticals LLC $247.00 06/06/2024 Non-covered Recipient Entity
Velocity Clinical Research Inc
NB (Contrave) Cardiovascular Outcomes Trial No dispute reported 06/30/2026 1089519447
Principal investigator 1 ModernaTX, Inc. $1,300.00 06/06/2024 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1147141562
Principal investigator 1 ModernaTX, Inc. $100.50 06/04/2024 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH- NEW MEXICO
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1147152477
Principal investigator 1 ModernaTX, Inc. $17,152.27 05/31/2024 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1147141430
Principal investigator 1 ModernaTX, Inc. $4,048.33 05/29/2024 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1147133575
Principal investigator 1 ModernaTX, Inc. $2,046.60 05/27/2024 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 2, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial Virus Disease No dispute reported 06/30/2026 1147141454
Principal investigator 1 ModernaTX, Inc. $257.66 05/03/2024 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1147133609
Principal investigator 1 ModernaTX, Inc. $100.00 05/02/2024 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1147141346
Principal investigator 1 ModernaTX, Inc. $7,474.24 04/24/2024 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, randomized, observerblind, activecontrol study to evaluate the safety, reactogenicity, and immunogenicity of mRNA1083 (SARSCoV2 and influenza) vaccine in healthy adult participants, 50 years of age. No dispute reported 06/30/2026 1147132887
Principal investigator 1 ModernaTX, Inc. $4,895.54 04/24/2024 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1147133283
Principal investigator 1 SANOFI PASTEUR INC. $1,536.97 04/24/2024 Non-covered Recipient Entity
Velocity Clinical Research,inc
A Phase I/II, Randomized, Descriptive, Safety and Immunogenicity Study to Assess Pentavalent Meningococcal ABCYW Vaccine Formulations in Adults (18 to 25 Years of Age) and Adolescents (10 to 17 Years of Age). No dispute reported 06/30/2026 1128703080
Principal investigator 1 ModernaTX, Inc. $135.00 04/19/2024 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 2, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial Virus Disease No dispute reported 06/30/2026 1147141260
Principal investigator 1 ModernaTX, Inc. $6,830.31 04/12/2024 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1147133311
Principal investigator 1 ModernaTX, Inc. $908.69 04/10/2024 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1147133331
Principal investigator 1 ModernaTX, Inc. $22,821.79 04/05/2024 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1147141246
Principal investigator 1 SANOFI PASTEUR INC. $200.00 04/01/2024 Non-covered Recipient Entity
Velocity Clinical Research,inc
A Phase I/II, Randomized, Descriptive, Safety and Immunogenicity Study to Assess Pentavalent Meningococcal ABCYW Vaccine Formulations in Adults (18 to 25 Years of Age) and Adolescents (10 to 17 Years of Age). No dispute reported 06/30/2026 1128703332
Principal investigator 1 ModernaTX, Inc. $51,888.90 03/28/2024 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1147141018
Principal investigator 1 ModernaTX, Inc. $1,534.95 03/28/2024 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 2, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial Virus Disease No dispute reported 06/30/2026 1147141064
Principal investigator 1 ModernaTX, Inc. $12,568.50 03/27/2024 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
Phase 1/2a randomized, observer-blind, placebo-controlled, dose-ranging study of safety and immunogenicity of mRNA-1647 cytomegalovirus (CMV) vaccine in participants 9 to 15 years of age and open-label study of safety and immunogenicity of mRNA-1647 CMV vaccine in participants 9 to 25 years of age No dispute reported 06/30/2026 1147132673
Principal investigator 1 ModernaTX, Inc. $1,664.00 03/27/2024 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1147132689
Principal investigator 1 ModernaTX, Inc. $5,448.60 03/21/2024 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 2, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial Virus Disease No dispute reported 06/30/2026 1147141044
Principal investigator 1 ModernaTX, Inc. $2,057.51 03/20/2024 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1147132715
Principal investigator 1 SANOFI PASTEUR INC. $5,075.06 03/18/2024 Non-covered Recipient Entity
Velocity Clinical Research,inc
A Phase I/II, Randomized, Descriptive, Safety and Immunogenicity Study to Assess Pentavalent Meningococcal ABCYW Vaccine Formulations in Adults (18 to 25 Years of Age) and Adolescents (10 to 17 Years of Age). No dispute reported 06/30/2026 1128702968
Principal investigator 1 SANOFI PASTEUR INC. $6,612.03 03/18/2024 Non-covered Recipient Entity
Velocity Clinical Research,inc
A Phase I/II, Randomized, Descriptive, Safety and Immunogenicity Study to Assess Pentavalent Meningococcal ABCYW Vaccine Formulations in Adults (18 to 25 Years of Age) and Adolescents (10 to 17 Years of Age). No dispute reported 06/30/2026 1128702976
Principal investigator 1 ModernaTX, Inc. $5,273.10 03/15/2024 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
Phase 1/2a randomized, observer-blind, placebo-controlled, dose-ranging study of safety and immunogenicity of mRNA-1647 cytomegalovirus (CMV) vaccine in participants 9 to 15 years of age and open-label study of safety and immunogenicity of mRNA-1647 CMV vaccine in participants 9 to 25 years of age No dispute reported 06/30/2026 1147132677
Principal investigator 1 ModernaTX, Inc. $225.00 03/15/2024 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1147132699
Principal investigator 1 ModernaTX, Inc. $923.00 03/15/2024 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1147132701
Principal investigator 1 ModernaTX, Inc. $43,900.72 03/08/2024 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, randomized, observerblind, activecontrol study to evaluate the safety, reactogenicity, and immunogenicity of mRNA1083 (SARSCoV2 and influenza) vaccine in healthy adult participants, 50 years of age. No dispute reported 06/30/2026 1147132417
Principal investigator 1 ModernaTX, Inc. $2,614.49 03/08/2024 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1147132745
Principal investigator 1 ModernaTX, Inc. $28,031.40 02/28/2024 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 2, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial Virus Disease No dispute reported 06/30/2026 1147140820
Principal investigator 1 Merck Sharp & Dohme LLC $14,500.00 02/24/2024 Non-covered Recipient Entity
Velocity Clinical Research, Albuquerque
A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Children and Adolescents With Increased Risk of Pneumococcal Disease No dispute reported 06/30/2026 1136434463
Principal investigator 1 ModernaTX, Inc. $1,608.39 02/22/2024 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1147140790
Principal investigator 1 ModernaTX, Inc. $150.00 02/21/2024 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1147132049
Principal investigator 1 ModernaTX, Inc. $357.50 02/21/2024 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1147132051
Principal investigator 1 ModernaTX, Inc. $877.50 02/21/2024 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1147132061
Principal investigator 1 ModernaTX, Inc. $375.00 02/21/2024 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1147132063
Principal investigator 1 ModernaTX, Inc. $2,574.18 02/16/2024 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1147140782
Principal investigator 1 ModernaTX, Inc. $55,991.00 02/14/2024 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1147132087
Principal investigator 1 ModernaTX, Inc. $12,593.29 02/09/2024 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1147132067
Principal investigator 1 ModernaTX, Inc. $84.50 02/07/2024 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1147131999
Principal investigator 1 ModernaTX, Inc. $825.00 02/01/2024 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1147132001
Principal investigator 1 ModernaTX, Inc. $8,000.00 02/01/2024 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1147132009
Principal investigator 1 ModernaTX, Inc. $1,780.00 02/01/2024 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1147132011
Principal investigator 1 ModernaTX, Inc. $500.00 02/01/2024 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1147132013
Principal investigator 1 ModernaTX, Inc. $1,174.50 01/24/2024 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
Phase 1/2a randomized, observer-blind, placebo-controlled, dose-ranging study of safety and immunogenicity of mRNA-1647 cytomegalovirus (CMV) vaccine in participants 9 to 15 years of age and open-label study of safety and immunogenicity of mRNA-1647 CMV vaccine in participants 9 to 25 years of age No dispute reported 06/30/2026 1147131703
Principal investigator 1 ModernaTX, Inc. $4,334.10 01/17/2024 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1147131683
Principal investigator 1 ModernaTX, Inc. $1,665.90 01/17/2024 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1147131685
Principal investigator 1 ModernaTX, Inc. $63,988.47 01/16/2024 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1147140476
Principal investigator 1 PFIZER INC. $4,460.00 01/10/2024 Non-covered Recipient Entity
Velocity Clinical Research Inc
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1131106512
Principal investigator 1 PFIZER INC. $1,700.00 01/03/2024 Non-covered Recipient Entity
Velocity Clinical Research Inc
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1131108495